FastWave Medical has been issued its fifth utility patent by the United States Patent and Trademark Office (USPTO), a press release reveals.
“FastWave’s IVL [intravascular lithotripsy] systems have been designed with physician input to deliver meaningful improvements for the management of calcific disease, which is one of the most difficult challenges we face in treating blood flow-limiting vascular blockages,” said Peter Schneider (University of California San Francisco, San Francisco, USA). “I am excited to witness FastWave’s team making tremendous advancements with their IVL technology, supported by a growing IP portfolio.”
According to a company press release, the newly granted patent bolsters the innovative design of Fastwave’s next-generation IVL platform, aimed at overcoming challenges associated with treating calcified arteries in patients with occlusive vascular disease. By developing advanced lithotripsy platforms, FastWave aims to address gaps in existing IVL options while enhancing ease of use and patient safety, thereby reducing procedural complications.
“This issuance of FastWave‘s fifth patent from the USPTO marks another milestone for our company and demonstrates clear progress with our unique IVL portfolio,” commented Scott Nelson, co-founder and chief executive officer of FastWave Medical. “The FastWave team highly values the collaboration with our medical advisors, translating real-world insights into compelling clinical solutions for the benefit of physicians and their patients.”
